Pfizer and Arvinas have decided to out-license their lead program in the PROTAC collaboration after the candidate underperformed in late-stage trials. This pivot signifies a strategic withdrawal from this experimental modality, as the companies reassess their pipeline priorities. The shift may impact the PROTAC field, which aims to target proteins for degradation as a novel therapeutic mechanism, reflecting the challenges of translation beyond early promise.